Lantheus Holdings, Inc. $LNTH is Reinhart Partners LLC.’s 10th Largest Position

Reinhart Partners LLC. lifted its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 15.9% in the 4th quarter, HoldingsChannel.com reports. The firm owned 1,562,576 shares of the medical equipment provider’s stock after acquiring an additional 214,820 shares during the period. Lantheus comprises about 3.1% of Reinhart Partners LLC.’s holdings, making the stock its 10th biggest position. Reinhart Partners LLC.’s holdings in Lantheus were worth $103,990,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Norges Bank purchased a new position in shares of Lantheus in the 4th quarter valued at approximately $76,197,000. Eurizon Capital SGR S.p.A. purchased a new position in shares of Lantheus in the 4th quarter valued at approximately $95,000. Savant Capital LLC purchased a new position in shares of Lantheus in the 4th quarter valued at approximately $362,000. Intech Investment Management LLC raised its position in shares of Lantheus by 28.2% in the 4th quarter. Intech Investment Management LLC now owns 81,221 shares of the medical equipment provider’s stock valued at $5,405,000 after purchasing an additional 17,849 shares during the last quarter. Finally, Bleakley Financial Group LLC purchased a new position in shares of Lantheus in the 4th quarter valued at approximately $771,000. 99.06% of the stock is owned by hedge funds and other institutional investors.

Lantheus Price Performance

Shares of NASDAQ:LNTH opened at $96.30 on Wednesday. Lantheus Holdings, Inc. has a twelve month low of $47.25 and a twelve month high of $103.89. The company’s 50 day moving average is $86.04 and its 200 day moving average is $73.80. The company has a current ratio of 2.83, a quick ratio of 2.64 and a debt-to-equity ratio of 0.47. The company has a market cap of $6.27 billion, a PE ratio of 23.20 and a beta of -0.03.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share for the quarter, topping the consensus estimate of $1.25 by $0.21. Lantheus had a net margin of 18.05% and a return on equity of 29.32%. The company had revenue of $377.33 million for the quarter, compared to the consensus estimate of $354.48 million. During the same quarter in the prior year, the company earned $1.53 EPS. Lantheus’s quarterly revenue was up 1.2% on a year-over-year basis. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. On average, sell-side analysts forecast that Lantheus Holdings, Inc. will post 4.41 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on LNTH shares. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Lantheus in a research report on Tuesday, May 26th. Mizuho increased their price objective on shares of Lantheus from $100.00 to $115.00 and gave the company an “outperform” rating in a research report on Wednesday, May 27th. Citigroup reaffirmed an “outperform” rating on shares of Lantheus in a research report on Friday, May 8th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $94.00 price objective on shares of Lantheus in a research report on Thursday, May 7th. Finally, Truist Financial reaffirmed a “buy” rating and issued a $115.00 price objective (up from $98.00) on shares of Lantheus in a research report on Monday, May 11th. Eight research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $101.86.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.